Bavarian Nordic's partner Eurofarma has submitted a regulatory approval application for the chikungunya vaccine CHIKV VLP to Brazil's health agency Anvisa. This marks a key step in making the vaccine available in Brazil, which reports over half of global chikungunya cases and deaths. The vaccine, already approved in the US, Europe, and Canada, is a single-dose, non-infectious vaccine designed for individuals 12 and older. The approval could significantly aid in preventing chikungunya, a mosquito-borne disease causing severe joint pain and chronic symptoms in many patients.
Egoist Machines, backed by Y Combinator, has launched AI Passport, a secure system allowing users to store and manage their personal data and preferences across various AI assistants like ChatGPT and Claude. This tool addresses concerns about data pr...
Bavarian Nordic's partner Eurofarma has submitted an application to Brazil's health authority Anvisa for approval of the chikungunya vaccine CHIKV VLP, targeting prevention in people aged 12 and above. This marks a key step in making the vaccine avai...
The global sleep water enhancers market is projected to grow from $1.48 billion in 2026 to $2.32 billion by 2030, with a CAGR of 11.9%. This growth is driven by increasing prevalence of sleep disorders, consumer preference for non-pill sleep aids, an...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The multi-head liquid filling machine market is projected to grow from $1.22 billion in 2026 to $1.71 billion by 2030, at a CAGR of 8.7%. Growth is fueled by rising demand for automation, efficiency, and smart factory solutions, especially in the exp...
